This article (1) is being retracted at the request of the authors. The work is in two main parts. The first part is a description of the relevant characteristics of the human ovarian cancer cell lines used and an analysis of the efficacy of the combination of the HSP90 inhibitor 17-AAG with paclitaxel and carboplatin. The latter part shows the effect of the single agents and drug combinations on HSP90 client proteins and downstream effectors. All of the experiments in the article were carried out in the laboratory of the senior author A.L. Jackman. It has been brought to our attention that in the second part of the article, Figs. 5A, 5B, 6, 7, and 8 contained inappropriately assembled Western blots. N. Sain performed the experiments and processed the data and has taken primary responsibility for the flawed figures. The authors wish to sincerely apologize to the scientific community and deeply regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.
Skip Nav Destination
Article navigation
Retractions|
September 04 2018
Retraction: Potentiation of Paclitaxel Activity by the HSP90 Inhibitor 17-allylamino-17-demethoxygeldanamycin in Human Ovarian Carcinoma Cell Lines with High Levels of Activated AKT
Online Issn: 1538-8514
Print Issn: 1535-7163
©2018 American Association for Cancer Research.
2018
American Association for Cancer Research.
Mol Cancer Ther (2018) 17 (9): 2075.
- Split-Screen
- Views Icon Views
- Share Icon Share
-
Tools Icon
Tools
- Search Site
-
Article Versions Icon
Versions
- Version of Record September 4 2018
Citation
Retraction: Potentiation of Paclitaxel Activity by the HSP90 Inhibitor 17-allylamino-17-demethoxygeldanamycin in Human Ovarian Carcinoma Cell Lines with High Levels of Activated AKT. Mol Cancer Ther 1 September 2018; 17 (9): 2075. https://doi.org/10.1158/1535-7163.MCT-18-0595
Download citation file:
24
Views
0
Citations
Citing articles via
Advertisement